Edgewise Therapeutics Statistics
Total Valuation
EWTX has a market cap or net worth of $1.57 billion. The enterprise value is $1.13 billion.
Important Dates
The last earnings date was Thursday, May 8, 2025, before market open.
| Earnings Date | May 8, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
EWTX has 105.20 million shares outstanding. The number of shares has increased by 35.11% in one year.
| Current Share Class | 105.20M |
| Shares Outstanding | 105.20M |
| Shares Change (YoY) | +35.11% |
| Shares Change (QoQ) | +0.43% |
| Owned by Insiders (%) | 0.53% |
| Owned by Institutions (%) | 69.70% |
| Float | 74.32M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 3.30 |
| P/TBV Ratio | 3.65 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 20.99, with a Debt / Equity ratio of 0.01.
| Current Ratio | 20.99 |
| Quick Ratio | 20.67 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -30.29% and return on invested capital (ROIC) is -21.81%.
| Return on Equity (ROE) | -30.29% |
| Return on Assets (ROA) | -21.08% |
| Return on Invested Capital (ROIC) | -21.81% |
| Return on Capital Employed (ROCE) | -39.24% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.33M |
| Employee Count | 110 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -18.77% in the last 52 weeks. The beta is 0.37, so EWTX's price volatility has been lower than the market average.
| Beta (5Y) | 0.37 |
| 52-Week Price Change | -18.77% |
| 50-Day Moving Average | 18.59 |
| 200-Day Moving Average | 24.68 |
| Relative Strength Index (RSI) | 43.78 |
| Average Volume (20 Days) | 1,178,145 |
Short Selling Information
The latest short interest is 13.26 million, so 12.60% of the outstanding shares have been sold short.
| Short Interest | 13.26M |
| Short Previous Month | 12.85M |
| Short % of Shares Out | 12.60% |
| Short % of Float | 17.84% |
| Short Ratio (days to cover) | 4.91 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -170.04M |
| Pretax Income | -115.88M |
| Net Income | -146.09M |
| EBITDA | -167.93M |
| EBIT | -170.04M |
| Earnings Per Share (EPS) | -$1.55 |
Full Income StatementBalance Sheet
The company has $436.39 million in cash and $4.56 million in debt, giving a net cash position of $431.83 million or $4.10 per share.
| Cash & Cash Equivalents | 436.39M |
| Total Debt | 4.56M |
| Net Cash | 431.83M |
| Net Cash Per Share | $4.10 |
| Equity (Book Value) | 429.72M |
| Book Value Per Share | 4.51 |
| Working Capital | 422.06M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$118.30 million and capital expenditures -$1.06 million, giving a free cash flow of -$119.36 million.
| Operating Cash Flow | -118.30M |
| Capital Expenditures | -1.06M |
| Free Cash Flow | -119.36M |
| FCF Per Share | -$1.13 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |